低剂量替格瑞洛治疗稳定型冠心病的疗效及安全性

Efficacy and Safety of Low-dose Ticagrelor in the Treatment of Stable Coronary Heart Disease

目的分析稳定型冠心病临床采用低剂量替格瑞洛治疗的疗效与安全性。方法选取2018年3月~2019年3月在我院治疗的75稳定型冠心病患者为研究对象,采用随机数字表法分为A组、B组、C组三组,各25例,A组给予硫酸氢氯吡格雷片75mg/次,1次/d治疗,B组给予替格瑞洛片90 mg/次,2次/d,治疗,C组采用替格瑞洛片45 mg/次,2次/d治疗,比较三组临床治疗总有效率、治疗前与治疗7 d后血小板聚集率、不良心脑血管事件(心肌梗死、卒中、出血)发生情况。结果B组(96.00%)、C组(92.00%)总有效率均高于A组(76.00%)(P<0.05);C组与B组比较,差异无统计学意义(P>0.05);治疗前A组、B组、C组血小板聚集率比较,差异无统计学意义(P>0.05),治疗7 d后B组、C组血小板聚集率均低于A组(P<0.05),C组与B组比较,差异无统计学意义(P>0.05);三组治疗和随访期间均未出现严重不良反应,差异无统计学意义(P>0.05)。结论临床采用低剂量替格瑞洛治疗稳定型冠心病疗效确切,抗血小板效果良好,且可有效预防不良心脑血管事件发生。

Objective To analyze the efficacy and safety of low-dose ticagrelor in clinical treatment of stable coronary heart disease.Methods The 75 patients with stable coronary heart disease treated in our hospital from March 2018 to March 2019 were selected as the research object,and they were divided into three groups of group A,group B,and group C by random number table method,with 25 cases in each group.Group A was given clopidogrel bisulfate tablets 75 mg/time,once a day,group B was given ticagrelor tablets 90 mg/time,twice a day,and group C was given ticagrelor tablets 45 mg/time,2 times/d treatment,compare the total clinical treatment efficiency of three groups,the platelet aggregation rate before treatment and 7 d after treatment,and the occurrence of adverse cardiovascular and cerebrovascular events(myocardial infarction,stroke,bleeding).Results The total effective rate of group B(96.00%)and group C(92.00%)was higher than that of group A(76.00%)(P<0.05);the difference between group C and group B was not statistically significant(P>0.05);before treatment,there was no statistically significant difference in platelet aggregation rate between group A,group B and group C(P>0.05).After 7 d of treatment,the platelet aggregation rate in group B and group C was lower than that in group A(P<0.05).There was no statistically significant difference between group C and group B(P>0.05);no serious adverse reactions occurred in the three groups during treatment and follow-up,the difference was not statistically significant(P>0.05).Conclusion Low-dose ticagrelor is effective in the treatment of stable coronary heart disease,with good antiplatelet effect,and can effectively prevent the occurrence of adverse cardiovascular and cerebrovascular events.